QV Bioelectronics secures £2m in pre-series a funding to advance brain tumour device trials
The pre-series a financing was led by Science Angel Syndicate and Fink Family Office to support pre-clinical studies for the GRACE implant.
QV Bioelectronics develops surgical medical devices using electric field therapy to treat brain tumours. Its lead product is an implantable device aimed at glioblastoma.
QV Bioelectronics has raised £2m in a pre-series a financing round led jointly by Science Angel Syndicate and Fink Family Office. The company plans to apply the fresh capital towards completing pre-clinical studies and device design for its flagship brain tumour treatment, GRACE.
Additional backing for the round came from Northern Gritstone, Elbow Beach Capital, and returning investors SOSV and Catapult Ventures. The funding marks an important milestone as the medtech start-up prepares to take its electric field therapy technology into clinical trials.
Use of funds
- 01Fund research and development
- 02Scale operations
Investors
Science Angel Syndicate
Fink Family Office
Northern Gritstone
Elbow Beach Capital
SOSV
Catapult Ventures
Categories
About the company
QV Bioelectronics
QV Bioelectronics builds surgically implanted electric field therapy devices to treat brain tumours.